chlorambucil has been researched along with Abnormal Karyotype in 1 studies
Chlorambucil: A nitrogen mustard alkylating agent used as antineoplastic for chronic lymphocytic leukemia, Hodgkin's disease, and others. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed)
chlorambucil : A monocarboxylic acid that is butanoic acid substituted at position 4 by a 4-[bis(2-chloroethyl)amino]phenyl group. A chemotherapy drug that can be used in combination with the antibody obinutuzumab for the treatment of chronic lymphocytic leukemia.
Abnormal Karyotype: A variation from the normal set of chromosomes characteristic of a species.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Genetic instability is a feature of chronic lymphocytic leukemia (CLL) with adverse prognosis." | 2.82 | Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy. ( Altmüller, J; Bahlo, J; Crispatzu, G; Döhner, H; Engelke, A; Fischer, K; Goede, V; Hallek, M; Herling, CD; Herling, M; Klaumünzer, M; Kluth, S; Kreuzer, KA; Nürnberg, P; Reinhardt, HC; Rocha, CK; Schiller, J; Stilgenbauer, S; Tausch, E; Thiele, H, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Herling, CD | 1 |
| Klaumünzer, M | 1 |
| Rocha, CK | 1 |
| Altmüller, J | 1 |
| Thiele, H | 1 |
| Bahlo, J | 1 |
| Kluth, S | 1 |
| Crispatzu, G | 1 |
| Herling, M | 1 |
| Schiller, J | 1 |
| Engelke, A | 1 |
| Tausch, E | 1 |
| Döhner, H | 1 |
| Fischer, K | 1 |
| Goede, V | 1 |
| Nürnberg, P | 1 |
| Reinhardt, HC | 1 |
| Stilgenbauer, S | 1 |
| Hallek, M | 1 |
| Kreuzer, KA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective Cohort of Obinutuzumab and Chlorambucil (GC) Chemotherapy for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia Including Next- Generation Sequencing (NGS)-Based Assessment[NCT04059081] | Phase 2 | 31 participants (Anticipated) | Interventional | 2019-07-09 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for chlorambucil and Abnormal Karyotype
| Article | Year |
|---|---|
Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy.
Topics: Abnormal Karyotype; Aged; Aged, 80 and over; Chlorambucil; Female; Humans; Leukemia, Lymphocytic, Ch | 2016 |